心泰医疗2025中期报告

中期報告Interim Report2025 Contents 291213414849535658 Definitions2Corporate Information9Financial Highlights12Management Discussion and Analysis13Other Information41Review Report48Consolidated Balance Sheet49Consolidated Income Statement53Consolidated Statement of Cash Flows56Consolidated Statement of58Changes in Owners’ EquityNotes to the 2025 Interim60Financial Statements Definitions In this report, the following expressions have the meanings setout below unless the context requires otherwise: Definitions “LAA” Definitions Definitions Corporate Information BOARD OF DIRECTORS Executive Director Ms. Chen Juan(Chairman) Non-Executive Directors Ms. Zhang YuxinMr. Fu ShanMr. Zhu Guanfu Independent Non-Executive Directors Ms. Chan Ka Lai VanessaMr. Zheng YufengMr. Zheng Junwei SUPERVISORS 20255 11 Ms. Wang XiaoyongMr. Qian WeidongMr. Wang Xinglin(appointment ceased on May 11, 2025) AUDIT COMMITTEE Ms. Chan Ka Lai Vanessa(Chairperson)Mr. Zhu GuanfuMr. Zheng Yufeng REMUNERATION COMMITTEE Mr. Zheng Yufeng(Chairperson)Ms. Chen JuanMr. Fu ShanMs. Chan Ka Lai VanessaMr. Zheng Junwei NOMINATION COMMITTEE Ms. Chen Juan(Chairperson)Mr. Zhu GuanfuMs. Chan Ka Lai VanessaMr. Zheng YufengMr. Zheng Junwei Corporate Information JOINT COMPANY SECRETARIES Mr. Qin XueMr. Li Kin Wai AUTHORIZED REPRESENTATIVES Ms. Chen JuanMr. Li Kin Wai LEGAL ADDRESS IN THE PRC 25841201 Room 201Building 41No. 258, Xinzhuan RoadSongjiang DistrictShanghaiPRC ADDRESS OF HEAD OFFICE IN THE PRC 2584115 1/F, 5/FBuilding 41No. 258, Xinzhuan RoadSongjiang DistrictShanghaiPRC PRINCIPAL PLACE OF BUSINESS IN HONGKONG 33191918 Room 1918, 19/F, Lee Garden One33 Hysan AvenueCauseway BayHong Kong AUDITOR BDO China Shu Lun Pan Certified Public Accountants LLP Corporate Information LEGAL ADVISORS ••• As to Hong Kong lawWilson Sonsini Goodrich & Rosati As to PRC lawHaiwen & Partners HONG KONG SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong PRINCIPAL BANKS Bank of ShanghaiChina Merchants BankIndustrial and Commercial Bank of ChinaBank of Ningbo http://www.scientechmed.com/ COMPANY WEBSITE http://www.scientechmed.com/ 2022118 LISTING DATE November 8, 2022 STOCK CODE 2291 2291 Financial Highlights 2024630249.132.4%2025630329.7 –Revenue increased by 32.4% from RMB249.1 million forthe six months ended June 30, 2024 to RMB329.7 millionfor the six months ended June 30, 2025. –Gross profit increased by 25.4% from RMB226.7 millionfor the six months ended June 30, 2024 to RMB284.3million for the six months ended June 30, 2025. 2024630226.725.4%2025630284.3 2 0 2 463 021.717.0%202563025.4 –Research and development expenses increased by 17.0%from RMB21.7 million for the six months ended June 30,2024 to RMB25.4 million for the six months ended June30, 2025. 2 0 2 463 0140.229.8%2025630182.0 –Netprofit attributable to shareholders of the parentcompany increased by 29.8% from RMB140.2 million forthe six months ended June 30, 2024 to RMB182.0 millionfor the six months ended June 30, 2025. 2 0 2 56302024630 –The Board does not recommend the payment of an interimdividendfor the six months ended June 30,2025(sixmonths ended June 30, 2024: nil). Note: Certain amounts and percentage figures included in this report havebeen subject to rounding. Accordingly, figures shown as totals in certaintables may not be an arithmetic aggregation of the figures precedingthem. Any discrepancies in any table or chart between the total shownand the sum of the amounts listed are due to rounding. Management Discussion and Analysis BUSINESS REVIEW 20 Over the years, the Group has been focusing on the researchand development, manufacture and commercialization of heartdisease interventional medical devices. We have over 20 yearsof industry experience in the traditional metal medical devices,andwe have been successfully practicing degradability ofmedicaldevices in recent years,and at the same time,theCompanyis exploring the frontier fields of the heart valves,cardiacmechanical circulatory support,atrial septal punctureandother medical devices.As a leader in the interventionalmedical devices industry in China, we will continue to providesafe, effective, innovative and comprehensive medical solutionsin terms of breadth and depth. 30428 As of the date of this report, we had a total of 30 marketedoccluders, heart valves and accessory products, four productsunder registration review and preparation for registration and28product candidates in various stages of research anddevelopment such as occluders, heart valves and proceduralaccessories and mechanical circulatory support. The followingchartsummarizes the development status of our productportfolio up to the date of this report: Management Discussion and Analysis Management Discussion and Analysis Management Discussion and Analysis Management Discussion and Analysis Management Discussion and Analysis Management Discussio